Pacific Biosciences
PACB
150 hedge funds and large institutions have $733M invested in Pacific Biosciences in 2019 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 66 increasing their positions, 41 reducing their positions, and 25 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 41
0.9% less ownership
Funds ownership: 80.03% → 79.13% (-0.9%)
2% less call options, than puts
Call options by funds: $1.2M | Put options by funds: $1.22M
6% less funds holding
Funds holding: 160 → 150 (-10)
16% less capital invested
Capital invested by funds: $873M → $733M (-$141M)
24% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 25
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$17.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$12.4M |
| 3 |
VI
Versor Investments
New York
|
+$8.87M |
| 4 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
+$7.34M |
| 5 |
KLCMU
Kite Lake Capital Management (UK)
London,
United Kingdom
|
+$6.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$14.6M |
| 2 |
Citigroup
New York
|
-$14M |
| 3 |
BHMP
Bardin Hill Management Partners
New York
|
-$11.8M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$8.98M |
| 5 |
D.E. Shaw & Co
New York
|
-$8.12M |
PACB Hedge Fund Activity: Q2 2019 in Review
150 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q2 2019, worth a combined $733M — down 16% from $873M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of PACB and 19 opened new positions — a net loss of 6 holders — while 41 trimmed existing stakes and 66 added.
The largest buyer was Goldman Sachs, adding an estimated $17.1M. The largest seller was Millennium Management, cutting an estimated $14.6M.
- 150 institutional investors held Pacific Biosciences (PACB) as of Q2 2019, down from 160 in Q1 2019.
- Funds reported $733M of Pacific Biosciences stock for Q2 2019, down 16% quarter-over-quarter.
- 19 funds opened new Pacific Biosciences positions in Q2 2019 and 25 closed out, a net change of -6 holders.
- The largest Pacific Biosciences buyer in Q2 2019 was Goldman Sachs, an estimated $17.1M added.
- The largest Pacific Biosciences seller in Q2 2019 was Millennium Management, an estimated $14.6M sold.
Based on aggregated 13F filings for Q2 2019.